Abstract
The effect of novel azole derivatives (itraconazole and fluconazole) on 5-lipoxygenase activity was examined using human polymorphonuclear leukocytes (PMNL) as the enzyme source. The novel imidazole derivative itraconazole proved to be a potent inhibitor (IC50 2 X 10(-6) M) of 5-lipoxygenase activity. In contrast, fluconazole, an antifungal agent with bistriazole structure, had no effect on the Ca2+ ionophore A 23187-induced formation of 5-lipoxygenase metabolites in PMNL.
MeSH terms
-
Antifungal Agents / pharmacology
-
Arachidonate Lipoxygenases / antagonists & inhibitors*
-
Fluconazole / pharmacology*
-
Humans
-
Immunosuppressive Agents
-
In Vitro Techniques
-
Itraconazole
-
Ketoconazole / analogs & derivatives*
-
Ketoconazole / pharmacology
-
Lipoxygenase Inhibitors*
-
Neutrophils / drug effects
-
Neutrophils / enzymology
-
Neutrophils / immunology
Substances
-
Antifungal Agents
-
Immunosuppressive Agents
-
Lipoxygenase Inhibitors
-
Itraconazole
-
Fluconazole
-
Arachidonate Lipoxygenases
-
Ketoconazole